PE20211379A1 - Agentes inhibidores de ask1 - Google Patents
Agentes inhibidores de ask1Info
- Publication number
- PE20211379A1 PE20211379A1 PE2020002138A PE2020002138A PE20211379A1 PE 20211379 A1 PE20211379 A1 PE 20211379A1 PE 2020002138 A PE2020002138 A PE 2020002138A PE 2020002138 A PE2020002138 A PE 2020002138A PE 20211379 A1 PE20211379 A1 PE 20211379A1
- Authority
- PE
- Peru
- Prior art keywords
- triazol
- pyridin
- alkynyl
- alkenyl
- alkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Hospice & Palliative Care (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Esta referido a compuestos de Formula I, en donde: X es CR4 o N; n es 1 o 2; R1 es H, alquilo, alquenilo, alquinilo, halo, CN, C(O), entre otras opciones; R2 es H, alquilo, alquenilo, alquinilo, carbociclilo, heterociclilo; R3 es H, alquilo, alquenilo, alquinilo, carbociclilo, heterociclilo. Entre los compuestos preferidos tenemos los siguientes: N-(6-(4-Isopropil-4H-1,2,4-triazol-3-il)piridin-2-il)-2-metoxinicotinamida; (S)-2-Metoxi-N-(6-(4-(1,1,1-trifluoropropan-2-il)-4H-1,2,4-triazol-3-il)piridin-2-il)nicotinamida; 5-fluoro-2-Metoxi-N-(6-(4-(1-(trifluorometil)ciclopropil)-4H-1,2,4-triazol-3-il)piridin-2-il)nicotinamida. Estos compuestos inhiben la cinasa reguladora de las senales de apoptosis 1 (ASK1) y se emplean en el tratamiento de trastorno neurodegenerativo, enfermedad cardiovascular, trastorno metabolico, enfermedad inflamatoria, trastorno autoinmune, trastorno oseo destructivo, dolor, lesion cerebral traumatica, accidente cerebrovascular hemorragico, isquemia, hipoxia aguda, fibrosis del rinon (fibrosis renal), lesion renal, entre otros.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862690674P | 2018-06-27 | 2018-06-27 | |
| PCT/US2019/039156 WO2020006031A1 (en) | 2018-06-27 | 2019-06-26 | Ask1 inhibiting agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20211379A1 true PE20211379A1 (es) | 2021-07-27 |
Family
ID=67254023
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2020002138A PE20211379A1 (es) | 2018-06-27 | 2019-06-26 | Agentes inhibidores de ask1 |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US11814362B2 (es) |
| EP (1) | EP3814333A1 (es) |
| JP (1) | JP2021528456A (es) |
| KR (1) | KR20210024532A (es) |
| CN (1) | CN112638896A (es) |
| AR (1) | AR115636A1 (es) |
| AU (1) | AU2019291806A1 (es) |
| BR (1) | BR112020026423A2 (es) |
| CA (1) | CA3104662A1 (es) |
| CL (1) | CL2020003375A1 (es) |
| CO (1) | CO2021000782A2 (es) |
| CR (1) | CR20210049A (es) |
| EA (1) | EA202190034A1 (es) |
| IL (1) | IL279709A (es) |
| JO (1) | JOP20200318A1 (es) |
| MA (1) | MA53009A (es) |
| MX (1) | MX2020013895A (es) |
| PE (1) | PE20211379A1 (es) |
| SG (1) | SG11202012784SA (es) |
| TW (1) | TW202035389A (es) |
| UY (1) | UY38278A (es) |
| WO (1) | WO2020006031A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10669272B2 (en) | 2018-06-27 | 2020-06-02 | Bristol-Myers Squibb Company | Substituted naphthyridinone compounds useful as T cell activators |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4938949A (en) | 1988-09-12 | 1990-07-03 | University Of New York | Treatment of damaged bone marrow and dosage units therefor |
| TWI598347B (zh) * | 2009-07-13 | 2017-09-11 | 基利科學股份有限公司 | 調節細胞凋亡信號之激酶的抑制劑 |
| UY35212A (es) * | 2012-12-21 | 2014-06-30 | Gilead Sciences Inc | Inhibidores de la quinasa que regula la señal de la apoptosis |
| MX2016008254A (es) * | 2013-12-20 | 2016-10-14 | Gilead Sciences Inc | Inhibidores de cinasa reguladora de la señal de apoptosis. |
| WO2018151830A1 (en) | 2017-02-17 | 2018-08-23 | Fronthera U.S. Pharmaceuticals Llc | Pyridinyl based apoptosis signal-regulation kinase inhibitors |
-
2019
- 2019-06-26 SG SG11202012784SA patent/SG11202012784SA/en unknown
- 2019-06-26 EA EA202190034A patent/EA202190034A1/ru unknown
- 2019-06-26 US US17/253,269 patent/US11814362B2/en active Active
- 2019-06-26 CN CN201980042586.9A patent/CN112638896A/zh active Pending
- 2019-06-26 CR CR20210049A patent/CR20210049A/es unknown
- 2019-06-26 EP EP19739494.3A patent/EP3814333A1/en active Pending
- 2019-06-26 AR ARP190101780A patent/AR115636A1/es unknown
- 2019-06-26 MX MX2020013895A patent/MX2020013895A/es unknown
- 2019-06-26 MA MA053009A patent/MA53009A/fr unknown
- 2019-06-26 BR BR112020026423-7A patent/BR112020026423A2/pt not_active Application Discontinuation
- 2019-06-26 JP JP2020572645A patent/JP2021528456A/ja active Pending
- 2019-06-26 PE PE2020002138A patent/PE20211379A1/es unknown
- 2019-06-26 KR KR1020217000614A patent/KR20210024532A/ko unknown
- 2019-06-26 WO PCT/US2019/039156 patent/WO2020006031A1/en unknown
- 2019-06-26 CA CA3104662A patent/CA3104662A1/en not_active Abandoned
- 2019-06-26 UY UY0001038278A patent/UY38278A/es not_active Application Discontinuation
- 2019-06-26 AU AU2019291806A patent/AU2019291806A1/en not_active Abandoned
- 2019-06-26 JO JOP/2020/0318A patent/JOP20200318A1/ar unknown
- 2019-06-26 TW TW108122356A patent/TW202035389A/zh unknown
-
2020
- 2020-12-23 IL IL279709A patent/IL279709A/en unknown
- 2020-12-23 CL CL2020003375A patent/CL2020003375A1/es unknown
-
2021
- 2021-01-25 CO CONC2021/0000782A patent/CO2021000782A2/es unknown
-
2023
- 2023-10-05 US US18/377,125 patent/US20240109867A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MA53009A (fr) | 2021-05-05 |
| CO2021000782A2 (es) | 2021-01-29 |
| EA202190034A1 (ru) | 2021-04-08 |
| US20210115020A1 (en) | 2021-04-22 |
| TW202035389A (zh) | 2020-10-01 |
| WO2020006031A1 (en) | 2020-01-02 |
| AU2019291806A1 (en) | 2021-01-07 |
| US20240109867A1 (en) | 2024-04-04 |
| IL279709A (en) | 2021-03-01 |
| CA3104662A1 (en) | 2020-01-02 |
| EP3814333A1 (en) | 2021-05-05 |
| MX2020013895A (es) | 2021-07-21 |
| UY38278A (es) | 2020-01-31 |
| US11814362B2 (en) | 2023-11-14 |
| AR115636A1 (es) | 2021-02-10 |
| KR20210024532A (ko) | 2021-03-05 |
| CL2020003375A1 (es) | 2021-09-03 |
| WO2020006031A8 (en) | 2020-09-24 |
| JOP20200318A1 (ar) | 2020-12-10 |
| JP2021528456A (ja) | 2021-10-21 |
| CN112638896A (zh) | 2021-04-09 |
| BR112020026423A2 (pt) | 2021-03-23 |
| CR20210049A (es) | 2021-07-01 |
| SG11202012784SA (en) | 2021-01-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2019001988A1 (es) | Compuestos químicos como inhibidores de actividad interleuquina-2. | |
| PE20211810A1 (es) | Compuestos novedosos | |
| EA202092896A1 (ru) | Гетероциклические и гетероарильные соединения для лечения болезни гентингтона | |
| EA201891229A1 (ru) | Eif4a-ингибирующие соединения и связанные с ними способы | |
| CL2017002922A1 (es) | Agonistas de triazol del receptor apj | |
| SA518392101B1 (ar) | ROR-Gamma مشتقات البنزيميدازول في صورة مُعدلات لـ | |
| EA201992322A3 (ru) | Соединения и композиции для лечения гематологических расстройств | |
| EA202090256A1 (ru) | 5-членные и бициклические гетероциклические амиды в качестве ингибиторов rock | |
| PE20161443A1 (es) | Compuestos | |
| PE20170331A1 (es) | Derivados quinolina como inhibidores smo | |
| CU20180131A7 (es) | Forma polimorfa de n-{6-(2-hidroxipropan-2-il)-2-[2-(metilsulfonil)etil]-2h-indazol-5-il}-6-(trifluorometil)piridin-2-carboxamida | |
| PE20181144A1 (es) | Derivados de heteroarilo como inhibidores de parp | |
| EA201692249A1 (ru) | Ингибиторы фосфатидилинозитол-3-киназы | |
| PE20190806A1 (es) | Agonistas heterociclicos del receptor de apelina (apj) y usos de los mismos | |
| MA50441A (fr) | Nouvelle association d'agents actifs pour le traitement de pneumopathies interstitielles fibrosantes progressives (pf-ild) | |
| EA201692260A1 (ru) | Соединения 1,3,4-тиадиазола и их применение в лечении рака | |
| PE20200740A1 (es) | Analogos de benzoazepina como agentes inhibidores de la tirosina cinasa de bruton | |
| PE20211379A1 (es) | Agentes inhibidores de ask1 | |
| MA41633B1 (fr) | Composés amide en tant qu'agonistes du récepteur 5-ht4 | |
| PE20191792A1 (es) | Derivados de isoxazol como agonistas del receptor nuclear y usos de los mismos | |
| EA202092084A1 (ru) | Соединения - агонисты фактора роста и дифференцировки 15 и способы их применения | |
| EA201891644A1 (ru) | Антибактериальные соединения и их применение | |
| EA201990678A1 (ru) | Гетероарилкарбоксамидные соединения в качестве ингибиторов ripk2 | |
| MX2019012827A (es) | Derivados de tetrahidronaftilo urea novedosos. | |
| EA201791667A1 (ru) | Соединения бензоксаборола и их применение |